Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02291003
Other study ID # STU00096215
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 29, 2015
Est. completion date September 30, 2017

Study information

Verified date August 2018
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Circadian clocks are not only found in discrete areas of the brain, but are found in virtually every organ in our bodies, including the heart, lungs and immune system. Disruptions in circadian clocks, or chronopathology, may underlie various forms of cardiovascular, pulmonary, and metabolic disorders. Over the past two decades, molecular geneticists have "cracked" the clock to reveal its core biochemical mechanisms evident in organisms from fruit flies to humans. These mechanistic insights have led to the discovery of links between clock function and an ever-expanding array of prevalent diseases, including heart, lung, metabolic and sleep disorders. Yet the prevalence of circadian disruption in these patient populations is unclear because current tests are not easily applied in clinical settings or have yet to be developed. Here the investigators exploit our newfound understanding of clock mechanisms and the development of new genomic technologies to identify novel complements of clock-regulated genes ("signatures") that will reveal the state of the internal biological clock. This approach will allow us to take a genomic snapshot of clock status from a single blood draw, substantially easing the diagnosis of these individuals with evidence of circadian disruption or misalignment, i.e., chronopathology.


Description:

Circadian clocks are not only found in discrete areas of the brain, but are found in virtually every organ in our bodies, including the heart, lungs and immune system. Disruptions in circadian clocks, or chronopathology, may underlie various forms of cardiovascular, pulmonary, and metabolic disorders. Over the past two decades, molecular geneticists have "cracked" the clock to reveal its core biochemical mechanisms evident in organisms from fruit flies to humans. These mechanistic insights have led to the discovery of links between clock function and an ever-expanding array of prevalent diseases, including heart, lung, metabolic and sleep disorders. Yet the prevalence of circadian disruption in these patient populations is unclear because current tests are not easily applied in clinical settings or have yet to be developed. Perhaps the major limitation of these techniques is the need for serial sampling over extended periods of at least 24 hours and in some cases longer. The development of an assay from a single blood draw would represent a major step forward, facilitating assessments of circadian disruption in a range of diseases.

An alternative strategy to existing assays is to use genomic microarrays to analyze circadian rhythms. Many studies in a number of organisms as well as multiple organs and tissues have found that substantial fractions of the genome (2-10%) are under robust circadian clock control. Importantly, these hundreds of rhythmic genes exhibit expression peaks at all times throughout the day, presumably reflecting their time-of-day specific functions. Using this as a foundation, Ueda and colleagues proposed an alternative strategy that would allow assessment of circadian time from a single blood draw allowing more routine assessments of circadian clock state. In brief, they identified the complement of rhythmic genes in livers of mice. They then selected a set of approximately 50 genes with unique peak times as "time-indicating genes." They then assessed the transcript levels of these time-indicating genes at a single time of day and found that they could accurately determine the time of day that the liver was taken based on the relative expression levels of the time-indicating genes. These studies provide proof-of-principle for the approach that we propose here. Establishing a molecular assay in humans for circadian rhythms from a single time point will allow us to identify circadian rhythm disorders, and to assess internal biological time to deliver therapies at their most efficacious time.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date September 30, 2017
Est. primary completion date December 16, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Healthy controls

- Age 18-60

- Intermediate circadian chronotype as determined by the Horne-Ostberg and Munich questionnaire

- Habitual sleep start times between 9:30pm and 1am

- Habitual sleep duration of 6-9 hours

Exclusion Criteria:

- History or current Diagnostic and Statistical Manual-V major psychiatric disorder

- Use of psychoactive medications

- Beck Depression inventory = 16 indicating possible depression

- A history or current diagnosis of a primary sleep disorder (insomnia, sleep apnea, circadian rhythm sleep disorder, restless legs)

- Shift work or other types of self-imposed irregular sleep/wake cycles

- History of, or concurrent unstable or serious medical illness

- Allergy to heparin

- Blindness or other visual impairment other than glasses

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Circadian gene expression profile The circadian pattern of gene expression will be determined through collecting saliva and blood at regular intervals over a 24 hour and analyzing with microarrays. 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT04578249 - Effects of Blocking Blue Light at Night Post CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH N/A
Recruiting NCT06129942 - Light Therapy in Parkinson's Disease N/A
Recruiting NCT06083831 - The Effect of Sequential Feeding for Circadian Rhythm and Gut Flora Rhythm in Critically Ill Patients
Recruiting NCT05228444 - Managing Sleep-wake Disruption Due to Hospitalisation: the Circadian Care Project N/A
Active, not recruiting NCT04953754 - Melatonin and Vaccine Response, Immunity, and Chronobiology Study N/A
Not yet recruiting NCT05452096 - SHIFTPLAN: an RCT Investigating the Effect of a Shift Work Intervention on Fatigue, Sleep and Health. N/A
Completed NCT01327040 - Light Sensitization Study N/A
Completed NCT03331822 - The Effects of Bright Light Exposure on ICU Nurses N/A
Completed NCT03646084 - Sleep and Circadian Intervention Program for Chronic Musculoskeletal Pain N/A
Recruiting NCT04690504 - Validation of Circadian Biomarkers in Patients With Sleep Disorders
Recruiting NCT06023654 - Identifying Circadian Rest-Activity Rhythm Disorders in Patients With Advanced Cancer
Completed NCT03682185 - The Healthy Patterns Sleep Study Phase 3
Recruiting NCT06346613 - Prevalence and Affecting Factors of Sleep and Circadian Rhythm Disorders in ICU
Recruiting NCT05309577 - Self-Care for Dementia Caregivers N/A
Completed NCT04157244 - The Music, Sleep and Dementia Study N/A
Completed NCT03468400 - Evaluation of the Reliability and Validity of a Diagnostic Sleep Disorders Questionnaire
Recruiting NCT04063332 - Functionality of Endogenous Biological Clock in Sepsis
Recruiting NCT06329479 - A Feasibility Trial for Circadian Rest-activity Rhythm Disorders in Cancer (RALI) N/A
Recruiting NCT04401189 - The Role of Circadian Rhythms in Cancer-Related Symptoms
Completed NCT03684460 - Daytime Bright Light, Circadian Abnormalities, and Delirium in Medical ICU Patients N/A